ASTRO Annual Meeting | Conferences

Study Shows H-RT Is Safe, Effective for Low-Risk Prostate Cancer

October 21, 2016

Study results that examined patient-reported outcomes and quality of life measures demonstrate that hypofractionated radiotherapy (H-RT) is a viable, safe, and value-added alternative to patients with low-risk prostate cancer.

Low-Risk Meningioma Study Adds Clarity to Irradiation Role

October 21, 2016

Patients with low-risk meningioma had a 3-year progression-free survival (PFS) that modestly exceeded expectations after gross total resection followed by observation, results of a cooperative group trial showed.

Computer Simulation Helps Plan Transducer Placement in Glioblastoma

October 14, 2016

For patients who are likely to experience contiguous recurrence of glioblastoma, a new computer simulation using tumor treating fields (TTF) and employing a personalized transducer array, delivered electric field (EF) intensities that exceeded therapeutic intensities in 3 different tumor locations.

High Rates of Overall Survival Show Benefit of SBRT in Unresectable Liver Cancer

October 14, 2016

Results from a phase II study from Korea demonstrated high rates of tumor local control, overall survival (OS), and grade 1/2 gastrointestinal and hepatic toxicities in patients who received stereotactic body radiotherapy (SBRT) for unresectable hepatocellular carcinoma (HCC) after incomplete transarterial chemoembolization (TACE).

KRAS-Variant HNSCC Outcomes May Improve With Cetuximab

October 13, 2016

Patients with head and neck cancer whose disease is associated with KRAS variant had significantly better progression-free survival (PFS) and overall survival (OS) when treated with the monoclonal antibody cetuximab (Erbitux), according to findings of a retrospective analysis of a randomized trial.

No Benefit from Combined Irradiation in Intermediate-Risk Prostate Cancer

October 07, 2016

The addition of external-beam radiotherapy (EBRT) to interstitial brachytherapy failed to reduce prostate cancer progression compared to brachytherapy alone in men with intermediate-risk disease, interim data from a randomized trial showed.